HomeCompareSLRC vs ZBH

SLRC vs ZBH: Dividend Comparison 2026

SLRC yields 11.67% · ZBH yields 1.08%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRC wins by $22.0K in total portfolio value
10 years
SLRC
SLRC
● Live price
11.67%
Share price
$14.05
Annual div
$1.64
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.2K
Annual income
$2,420.32
Full SLRC calculator →
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →

Portfolio growth — SLRC vs ZBH

📍 SLRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRCZBH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRC + ZBH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRC pays
ZBH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRC
Annual income on $10K today (after 15% tax)
$992.17/yr
After 10yr DRIP, annual income (after tax)
$2,057.27/yr
ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
At 15% tax rate, SLRC beats the other by $1,956.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRC + ZBH for your $10,000?

SLRC: 50%ZBH: 50%
100% ZBH50/50100% SLRC
Portfolio after 10yr
$32.2K
Annual income
$1,269.48/yr
Blended yield
3.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ZBH right now

SLRC
Analyst Ratings
9
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$16.25
+15.7% upside vs current
Range: $16.00 — $16.50
Altman Z
0.5
Piotroski
4/9
ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRC buys
0
ZBH buys
0
No recent congressional trades found for SLRC or ZBH in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRCZBH
Forward yield11.67%1.08%
Annual dividend / share$1.64$0.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.2%
Portfolio after 10y$43.2K$21.2K
Annual income after 10y$2,420.32$118.64
Total dividends collected$17.8K$1.1K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusBuyHold
Analyst price target$16.25$105.60

Year-by-year: SLRC vs ZBH ($10,000, DRIP)

YearSLRC PortfolioSLRC Income/yrZBH PortfolioZBH Income/yrGap
1← crossover$11,867$1,167.26$10,809$108.54+$1.1KSLRC
2$13,993$1,294.60$11,675$109.86+$2.3KSLRC
3$16,399$1,426.58$12,603$111.13+$3.8KSLRC
4$19,109$1,562.51$13,598$112.34+$5.5KSLRC
5$22,148$1,701.65$14,663$113.51+$7.5KSLRC
6$25,542$1,843.27$15,804$114.62+$9.7KSLRC
7$29,317$1,986.64$17,026$115.69+$12.3KSLRC
8$33,500$2,131.05$18,335$116.71+$15.2KSLRC
9$38,121$2,275.83$19,736$117.70+$18.4KSLRC
10$43,209$2,420.32$21,236$118.64+$22.0KSLRC

SLRC vs ZBH: Complete Analysis 2026

SLRCBDC

SLR Investment Corp. is a business development company specializing in secured debt (first lien unitranche and second lien), subordinated (unsecured) debt, minority equity, leveraged buyouts, acquisitions, recapitalizations, general refinancing, growth capital and strategic income-oriented control equity investments in leveraged middle market companies. The fund invests in aerospace and defense; air freight & logistics; asset management; automotive; banking; beverage, food and tobacco; building products; buildings and real estate; broadcasting and entertainment; cargo transport; commercial services and supplies; communications equipment; chemicals, plastics and rubber; containers, packaging and glass; construction & engineering; diversified/conglomerate manufacturing; consumer Finance; distributors; diversified/conglomerate services; diversified financial services; diversified real estate activities; food products; Footwear; Education Services; diversified telecommunications services; electronics; farming and agriculture; finance; grocery; health care equipment and supplies; health care facilities; education and childcare; home and office furnishing, durable consumer products; hotels, motels, inns and gaming; insurance; restaurants, leisure, amusement, and entertainment; leisure equipment tolls and services, media, multiline retail, multi sector holdings; paper and forest products; personal products; professional services, research and consulting services, software; specialty retail; textiles apparel and luxury goods, thrifts and mortgage finance, trading companies and distributors, utilities, and wireless telecommunication services; industrial conglomerates; internet software and services, IT services, machinery; mining, steel, iron, and non-precious metals; oil and gas; personal, food and miscellaneous services; printing and publishing; retail stores; telecommunications; textiles and leather; and utilities. It also invests in life sciences with focus on specialty pharmaceuticals, medical devices, biotech, health Care Providers and services; health Care technology, enabling technologies and tools. The fund primarily invests in United States. The fund's investments generally range between $5 million and $100 million. The fund invests in companies with revenues between $50 million and $1 billion and EBITDA between $15 million and $100 million. It invests in the form of senior secured loans, mezzanine loans, and equity securities. It may also seek investments in thinly traded public companies and also make secondary investments. The fund makes non-control equity investments. It primarily exits within three years of the initial capital commitment.

Full SLRC Calculator →

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →
📬

Get this SLRC vs ZBH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRC vs SCHDSLRC vs JEPISLRC vs OSLRC vs KOSLRC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.